A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated
dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage
solid tumors.